‘Hope on the horizon' as drugs assessed for Alzheimer's prevention
Some 138 treatments are being assessed in clinical trials.
A third of drugs currently being trialled are 'repurposed' medications that are already being used to tackle other diseases, including diabetes, multiple sclerosis and cholesterol, according to the new review.
182
clinical trails are assessing treatments for Alzheimer's disease
One such trial is assessing whether semaglutide, the main ingredient for the weight loss and diabetes drug Ozempic and weight loss drug Wegovy, can slow the progression of dementia.
And four late-stage trials are looking at preventing disease.
Experts said that drugs targeting amyloid protein build up in the brain, such as lecanemab and donanemab, are 'only one part of the overall strategy' as they expressed excitement over the variety of new drugs, which are being tested among patients.
The new review of Alzheimer's disease in clinical trials in 2025 found 182 clinical trials assessing the impact of 138 drugs.
This latest report shows us that there is hope on the horizon for people with Alzheimer's Dr Sheona Scales
The number of trials represents an 11% increase on the previous year, according to the review, which was led by an expert from the University of Nevada in the US and has been published in the journal Alzheimer's and Dementia: Translational Research and Clinical Interventions.
Commenting on the paper, Dr Sheona Scales, director of research at Alzheimer's Research UK, said: 'This year has really given us real cause for optimism.'
She said that as well as more drugs coming through the pipeline, the treatment targets are 'more diverse' and 'looking at all stages of the disease'.
She added: 'What this paper is showing us is that the pipeline of drug development is growing, it's diversifying and accelerating.'
'This latest report shows us that there is hope on the horizon for people with Alzheimer's, building on lecanemab and donanemab.'
One of the most exciting things of this report is the number of large scale late-stage trials on prevention Prof James Rowe
Dr Emma Mead, chief scientific officer of the Oxford Drug Discovery Institute, added: 'Today we are at a tipping point in dementia research as we understand more and more about the diseases that drive dementia.
'This gives us opportunities to slow and ultimately stop this devastating condition and today's announcement demonstrates that researchers are able to translate these understandings towards potential new treatments.'
James Rowe, professor of cognitive neurology at the University of Cambridge and consultant neurologist, said: 'What strikes me is not just the number of new drugs, which is increasing year on year, but their range of targets (and) the range in which they work, giving us multiple shots on goal.'
On the drugs which are being investigated for the prevention of disease, Prof Rowe said: 'One of the most exciting things of this report is the number of large-scale late-stage trials on prevention.
'And the aspiration to prevent, not just treat, is starting to be seen in the figures we see in these charts today.'
He added: 'One way this can work is you take a treatment that you show to be working in people with symptoms with the illness, and then you simply bring it forward by some years.
'The ones that are in trial at the moment are really… bringing forward an effective treatment to earlier stage.'
Being able to repurpose drugs licenced for other health conditions could help to accelerate progress and help to open up other avenues for to prevent or treat dementia causing diseases Dr Emma Mead, chief scientific officer of the Oxford Drug Discovery Institute
For instance, people with a genetic risk of Alzheimer's could receive some drugs earlier to see if they protect against the disease.
On the repurposing of current drugs, Dr Mead said that it can usually take 10 to 15 years for new drugs to be tested and approved for use.
'Being able to repurpose drugs licensed for other health conditions could help to accelerate progress and help to open up other avenues to prevent or treat dementia causing diseases,' she said.
'A really promising example of this is the drug semaglutide, which is currently being trialled in people with mild cognitive impairment.'
Meanwhile, academics said lecanemab and donanemab, which can be used for treating mild cognitive impairment in Alzheimer's patients, are an 'important first step' in the battle against the disease.
The treatments were initially approved for UK use by regulators but then deemed not cost-effective for NHS use.
The National Institute for Health and Care Excellence (Nice) is taking more evidence on donanemab and lecanemab and is expected to announce its decision in the summer.
Dr Scales added: 'Lecanemab and donanemab have represented a huge leap forward in our understanding and ability to be able to treat Alzheimer's disease.
'What they've done is they've proved that we're able to modify the course of Alzheimer's disease, and what that has done is opened up the door to future treatments that we hope are more effective, easier to deliver and and able to deliver for our patients.'
She said studies are showing 'even more complexities' around Alzheimer's and that in the future, people may be treated with a combination of drugs, depending on when they are diagnosed and the type of dementia they have.
Dr Richard Oakley, associate director of research at Alzheimer's Society, said: 'This paper shows that 2025 is shaping up to be a landmark year for Alzheimer's disease drug development.
'With more trials under way than ever before and more drugs entering the pipeline, there is hope on the horizon for the nearly one million people living with dementia in the UK.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
an hour ago
- Daily Mail
EXCLUSIVE I invented the 'Death Clock'... and was horrified when it confirmed my worst fears about my own health
Brent Franson wasn't afraid of dying. He was afraid of dying from Alzheimer's disease. He remembers seeing sufferers on TV growing up, with their listless expressions and inability to walk. It left him certain he did not want to develop the devastating condition. His worst fear was revealed when he used the Death Clock - an artificial intelligence that predicts - down to the minute - when and how a person will die. Franson invented the app, which analyzes a person's body metrics and lifestyle, and input his own information. The 43-year-old was shocked when the Death Clock projected his demise at 76 years old. Among possible causes of his death: Alzheimer's. It made sense, Franson thought. In his 20s, he had become addicted to anti depressants and sedatives, which left him unable to sleep properly for a decade - a risk factor for neurological decline - and he had a gene that predisposed him to dementia. Franson was also working late, eating large late-night dinners and balancing his role as husband and father-of-three. Determined to change his fate, however, Franson made major lifestyle changes - becoming what he called a 'sleep athlete.' He fine-tuned his schedule to make time for rest and exercise and to create a better work-life balance. One year later, he ran his information through the Death Clock again and it revised its estimate — adding an extra nine years to his life expectancy. The most likely cause of death? Alzheimer's was still a possibility, but so were cardiovascular diseases and cancer. 'Something does have to kill you eventually,' Franson told He added: 'My biggest fear in life, it's not death. It's Alzheimer's. Just the thought of having to live with Alzheimer's — so this was really a wake-up call for me.' As the aging population of the US continues to grow, so will the rates of dementia. Currently, an estimated 6.8million Americans have Alzheimer's disease - the most common form of dementia - the vast majority of whom are over 65 years old. By 2050, this number is projected to rise to nearly 13 million. A lack of sleep - especially a lack of deep sleep - has been linked to an increased risk of Alzheimer's in numerous studies. Experts say it stops the body from clearing out waste products from the brain — raising the risk of dangerous amyloid beta protein clumps forming that raise someone's risk of the disease. More than one in three adults — 50 to 70million people — regularly do not meet the CDC's recommendation of at least seven hours of sleep every night. One study has suggested sleeping six or fewer hours per night before age 70 is linked to a 30 percent increased risk of dementia compared to people getting seven hours or more. It can also drive other unhealthy behaviors, like exercising less or eating more sugary treats, which can also raise risk. To boost his sleep, and slash his risk of Alzheimer's, Franson began by banning all mobile phones from the bedroom. He set a consistent bedtime of 9.30pm, and made sure to have his last meal at 5.30pm every night. Scientists say a consistent bedtime helps the body's circadian rhythm while eating too close to bedtime means the body is still digesting, disrupting sleep. Some suggest it can take three to four hours for a meal to transit into the intestines. He also lowered the bedroom temperature to 60 degrees Fahrenheit (15 degrees Celsius). Experts recommend sleeping at temperatures between 60 and 67 degrees to reduce the body's internal temperature and ensure a restful night's sleep. He had two sets of blackout blinds installed in his bedroom, as well. One that descends horizontally from the ceiling, and another that moves vertically across the window, to block out all light while he sleeps. Another lifestyle change was cutting out alcohol. Alcohol has also been linked to sleep disruption, reducing the amount of time spent in REM sleep — a stage for memory consolidation — disrupting the sleep cycle. The Alzheimer's Society says drinking alcohol also reduces the volume of the brain's white matter, which helps the brain transmit signals between different regions. This can lead to issues with the way the brain functions. Alcohol can also shrink the parts of the brain involved in memory. Franson also makes sure to exercise during the day, saying he alternates between weight lifting, cardio exercises and yoga. A July 2022 study published in the journal Neurology analyzed the health information of 501,400 people from a British health database over 11 years. Researchers found people who engaged in consistent vigorous activity — sports or working out — had a 35 percent reduced risk of developing dementia. Even people who reported completing household chores saw a benefit and had a 21 percent lower risk of dementia. A separate October 2022 meta-analysis of 38 international studies found people who engaged in activities like regularly walking, running, dancing, playing sports or swimming had a 17 percent reduced risk of developing Alzheimer's disease compared to those who did not. And while there is plenty of fancy and expensive health tech, Franson said sleep, diet and exercise are more than 90 percent of the puzzle of longevity. He added that nine percent was cancer screenings and about one percent was 'all this crazy stuff that people like to talk about.' Franson added: 'The discussion in the longevity space is often focused on the wrong thing. 'People devote a lot of time talking about things like Ashwaganda or full-body scans when, compared to sleep, diet and exercise, these are going to make only tiny incremental differences.'
Telegraph
9 hours ago
- Telegraph
Weight-loss jabs can stop HRT working, doctors warn
Weight-loss drugs could stop hormone replacement therapy from working and increase the associated risks, guidance has warned. The British Menopause Society has told doctors to closely monitor any women who are on hormone replacement therapy (HRT) for the menopause and are also taking a weight-loss jab. The injections, such as Mounjaro and Wegovy, also sold as Ozempic for diabetes, have revolutionised obesity treatment and are increasingly taken by people who are not obese but looking to lose a few pounds. But the drug's ability to delay the transit of food through the gut can slow the absorption of pills taken orally. It is one theory behind the so-called ' Ozempic baby boom '. Earlier this week, the medicines regulator issued a warning about the impact of weight-loss drugs on contraception after receiving more than 40 reports relating to pregnancies from women on the jabs. The Medicines and Healthcare products Regulatory Agency said women should 'not rely on oral contraception' and warned them not to use the injections if pregnant or trying to get pregnant because of a lack of safety evidence. Guidance has now suggested women taking HRT orally may also be at risk. There were 2.6 million women taking HRT in 2023-24 in England to help with symptoms of the menopause, which can include hot flushes, night sweats, difficulty sleeping, mood changes, and muscle aches. It typically onsets between age 45 and 55 and can last for a number of years. The most common form of HRT is a progesterone pill alongside a skin patch or gel to deliver oestrogen, although some women will be on a combined pill. The progesterone is important to balance out the effects of oestrogen, which on its own stimulates the growth of the womb lining, and can cause ' abnormal cells and cancer ' to grow. The loss of the protective effect of progesterone on the womb was the primary concern for the British Menopause Society, which recommended doctors move women to an intrauterine device, such as a Mirena coil, or increase the dose of progesterone. Prof Annice Mukherjee, a consultant endocrinologist and member of the society's medical advisory council, who led on the guidance, said an imbalance in the hormones, particularly among women with obesity, would put them 'at increased risk of womb cancer '. 'Oestrogen is almost always given through the skin for HRT in women living with obesity, but progesterone is frequently given as a tablet, and that formulation is thought to be the safest route for women who have complicated health issues,' she said. 'If we then start one of these injectable weight-loss drugs, then you're preferentially stopping absorption of the progestogen that's coming in orally, but you're allowing plenty of the oestrogen through the skin. 'The rules are very clear that if you give a very high dose of oestrogen and you don't give enough progesterone, however that happens, you're putting that woman at risk of womb cancer,' she said. Prof Mukherjee said there was currently a 'culture of putting women on very high doses of oestrogen', which can make the womb lining thicken. 'It's like having a lawn in a woman's womb. Oestrogen makes the lawn grow. Progestogen cuts the lawn. But if it's not being cut, it grows thicker, and then you can get abnormal cells and cancer.' But she also stressed that the biggest risk factor for womb cancer was obesity and so on the whole the weight-loss injections were a positive tool to reduce weight and cancer risk. 'These drugs reduce the risk of cancer,' she said. 'But if they are prescribed to a woman who's on oestrogen through the skin, and she might already have womb thickening because she's living with obesity, and she's not absorbing the progesterone because she's been put on a weight-loss injection, she's potentially getting loads of oestrogen on top of her thickened womb lining, and that could potentially unmask cancers that are there or drive an early cancer to a more advanced stage.' More than 1.5 million people in the UK are now taking weight-loss jabs, with demand doubling in the last six months. The overwhelming majority are accessing them privately from pharmacies at a cost of around £200 per month. It is not known how many people are on both drugs, but the British Menopause Society has created guidelines after calls from GPs for advice to give to patients. Dr Janet Barter, the president of the Faculty of Sexual and Reproductive Healthcare, said there was 'a small but growing body of evidence that the new diabetes and weight loss drugs, which can bring really positive improvements to people's health, can also cause vomiting and severe diarrhoea in some patients'. 'Obviously this could render any medication, such as HRT tablets or oral contraception, ineffective if there hasn't been enough time for them to be fully absorbed,' she said. 'If these side-effects are occurring, then people should discuss the matter with their doctor or specialist clinician to find the combination of drugs that's right for them.'
Daily Mirror
18 hours ago
- Daily Mirror
Only people with hawk eyes can solve this football puzzle in under 60 seconds
Brainteasers are great for maintaining sharpness and concentration so here's a particularly tricky example only the most eagle-eyed can solve in under a minute With the Fifa Club World Cup around the corner, it's time for a fiendishly difficult brainteaser. Five footballs have been cleverly concealed within a picture of the pitch, presenting a challenge to even the most avid puzzle lovers. The brainteaser was created by Live Football Tickets, which said it takes readers 1 minute 23 seconds on average to complete. It claimed one in four people struggled to complete it altogether, challenging Mirror Online readers to get the job done in under 60 seconds. Don't worry, however - if the quiz proves too difficult, the answer can be found at the bottom of the article. Brainteasers prove popular because people enjoy the satisfaction of cracking puzzles and giving their mind a workout at the same time. Puzzles can enhance a range of skills including focus, logic, observation and reasoning too. They can also help you to switch off from daily stresses and strains, giving your brain a welcome sense of relief. So was your mind is sharp enough to beat the clock and find the hidden footballs? The answers are circled below. Brain workouts have been shown to help reduce the risk of dementia, with research showing 40 per cent of cases are preventable. The condition is a set of symptoms caused by different diseases, for example Alzheimer's, which can damage the brain and over time can affect memory, problem-solving, language and behaviour. Although ageing is one of the biggest risk factors for developing the condition, evidence shows that there are things you can do to reduce the risk. With regular practice, puzzles can help build up "cognitive reserve", which is a person's ability to cope with dementia, and is built up by keeping the brain active. The more cognitive reserve a person has "the longer it takes for any diseases in their brain to cause problems with everyday tasks," according to experts from the Alzheimer's Society. "People with a smaller cognitive reserve are at a higher risk of getting dementia in their lifetime," a spokesman from the charity added. "Our brains, like any other muscle in our bodies, require exercise to stay sharp," added psychologist Neha Cadabam. "Daily brainteasers serve as a mental workout, engaging different cognitive processes and pathways, which can have a remarkable impact on cognitive function, especially as we age. "Taking a moment to challenge our brains with a brain teaser can feel like a welcome mental respite," said the executive director at Cadabams Hospitals. "But beyond the immediate satisfaction of solving a puzzle, these little brain teasers might be doing a lot more for us than we realise."
